Form 8-K - Current report:
SEC Accession No. 0001214659-24-017549
Filing Date
2024-10-15
Accepted
2024-10-15 16:30:38
Documents
15
Period of Report
2024-10-15
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 o10142408k.htm   iXBRL 8-K 27877
2 EXHIBIT 99.1 ex99_1.htm EX-99.1 8909
6 GRAPHIC alzamendlogo_sm.jpg GRAPHIC 18173
  Complete submission text file 0001214659-24-017549.txt   243574

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE alzn-20241015.xsd EX-101.SCH 2991
4 XBRL LABEL FILE alzn-20241015_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE alzn-20241015_pre.xml EX-101.PRE 22343
17 EXTRACTED XBRL INSTANCE DOCUMENT o10142408k_htm.xml XML 3914
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 241372222
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)